Combination Therapy Target Identified for Kidney Cancer
Researchers identified a combination therapy that may help overcome drug resistance in clear cell renal cell carcinoma.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust laboratory findings on cancer treatments before they complete human clinical trials?
On September 9, 2026, researchers published findings on a new combination therapy for clear cell renal cell carcinoma. This preclinical development aims to address tumor resistance to standard drug treatments for this condition.
Why it matters
Tumors often develop resistance to existing treatments like belzutifan, limiting long-term effectiveness. This research offers a potential pathway to restore treatment sensitivity for patients managing this cancer.
In a preclinical study published in the Proceedings of the National Academy of Sciences, researchers demonstrated that combining recombinant TRAIL with the FDA-approved drug belzutifan increases tumor cell death in laboratory models compared to treatment with belzutifan alone.
The players
University of Notre Dame
A research university that conducted this study on renal cell carcinoma mechanisms.
University of Galway
A collaborating research institution that participated in the study of tumor cell death pathways.
The details
Clear cell renal cell carcinoma is linked to VHL gene mutations, which elevate HIF-2-alpha protein levels and trap natural TRAIL protein inside cells. Belzutifan reduces HIF-2-alpha to free these death receptors, allowing the introduced recombinant TRAIL to bind and trigger cancer cell death.
Timeline
September 09, 2026: Research article originally published.
September 30, 2026: Article republished by news.nd.edu.
Health Landscape
This study contributes to the clinical development pipeline for TRAIL-activating therapies by demonstrating how to restore receptor sensitivity in resistant cancer cells. It addresses the ongoing challenge of overcoming tumor resistance in standard oncological care.
This study is in the early preclinical stage and does not change current standard-of-care treatments or clinical guidance. Patients interested in how new research might eventually impact their care plan should discuss the latest clinical trial options with their oncologist.
The takeaway
While this laboratory finding shows promise for overcoming drug resistance in clear cell renal cell carcinoma, it is not yet available for patient use. Patients should continue working with their physicians to monitor current treatment responses and explore appropriate clinical trials.
Further reading
For more information on current treatment trends and research developments, visit Cancer.
Source note: This article includes information reported by Notre Dame News.
Live Poll
Do you trust laboratory findings on cancer treatments before they complete human clinical trials?
